Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 10184Triple Negative Breast Neoplasms 1046Neoplasms 574Ovarian Neoplasms 564Neoplasm Metastasis 515Colorectal Neoplasms 473Carcinoma, Non-Small-Cell Lung 468Prostatic Neoplasms 440Lung Neoplasms 433Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 295Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 227Endometrial Neoplasms 223Head and Neck Neoplasms 218Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 192Squamous Cell Carcinoma of Head and Neck 181Sarcoma 177Urinary Bladder Neoplasms 159Esophageal Neoplasms 155Brain Neoplasms 155Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 130

Interventions

fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Female Breast Cancer Patients × Breast × Clear all
NCT07357207 2026-01-23

VIT-BC

Izmir Biomedicine and Genome Center

Phase NA Enrolling by invitation
80 enrolled
Breast

Female Breast Cancer Patients

NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Female Breast Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡